210 related articles for article (PubMed ID: 30910893)
1. High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.
Bernal-Martínez L; Alcazar Fuoli L; Miguel-Revilla B; Carvalho A; Cuétara Garcia MS; Garcia-Rodriguez J; Cunha C; Gómez-García de la Pedrosa E; Gomez-Lopez A
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910893
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
[TBL] [Abstract][Full Text] [Related]
3. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
[TBL] [Abstract][Full Text] [Related]
6. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series.
Weigel JD; Hunfeld NG; Koch BC; Egal M; Bakker J; van Schaik RH; van Gelder T
Intensive Care Med; 2015 Nov; 41(11):2013-4. PubMed ID: 26239729
[No Abstract] [Full Text] [Related]
8. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
9. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?
Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027
[TBL] [Abstract][Full Text] [Related]
10. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.
Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T
Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512
[No Abstract] [Full Text] [Related]
11. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
12. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.
Moriyama B; Kadri S; Henning SA; Danner RL; Walsh TJ; Penzak SR
Curr Fungal Infect Rep; 2015 Jun; 9(2):74-87. PubMed ID: 26918067
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure.
Abidi MZ; D'Souza A; Kuppalli K; Ledeboer N; Hari P
Diagn Microbiol Infect Dis; 2015 Sep; 83(1):46-8. PubMed ID: 25986028
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclosporine a and polymorphisms in
Zeng G; Shi L; Li H; Wang L; Zhu M; Luo J; Zhang Z
Xenobiotica; 2020 May; 50(5):614-619. PubMed ID: 31573401
[TBL] [Abstract][Full Text] [Related]
17. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
19. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
Espinoza N; Galdames J; Navea D; Farfán MJ; Salas C
Sci Rep; 2019 Jun; 9(1):8863. PubMed ID: 31222084
[TBL] [Abstract][Full Text] [Related]
20. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
